Business Wire

CA-CYOLO

8.5.2024 14:31:36 CEST | Business Wire | Press release

Share
Cyolo Partners with Dragos to Unveil Holistic Secure Remote Access Solution for Critical Infrastructure

Cyolo, the secure remote access company for operational technology (OT) and industrial control systems (ICS), today announced a strategic partnership with Dragos, a global leader in cybersecurity for ICS/OT. Under the umbrella of Cyolo’s CyoloVerse partner program, Cyolo's PRO Secure Remote Access Platform will work with Dragos’s industry-leading OT cybersecurity platform. This collaboration will provide organizations with a robust and interoperable solution to protect their critical infrastructure against cyber threats.

New technology implementations in ICS/OT environments pose unique risks for critical infrastructure. Today’s risks include lack of support for modern authentication or connectivity methods in traditional environments, connecting existing infrastructure with highly vulnerable end-of-life operating systems, or risk of breaches from third-party remote access.

This interoperability is designed to provide OT customers visibility and management of their asset inventory and enhance asset vulnerability detection and remediation capabilities through a seamless secure controlled access platform.

“Cyolo ICS/OT security and safety expertise are changing the way organizations understand secure remote access,” said Matt Cowell, VP of Business Development at Dragos. “With our companies’ complementary capabilities and unique strengths, we can manage security through the different layers of the operational environment and protect a wider array of organizations across critical infrastructure. Ultimately reducing risk as they expand connectivity.”

Bringing the Cyolo PRO platform alongside the Dragos OT-native network visibility and monitoring offerings gives an unparalleled advantage. The Dragos Platform enables organizations to scale protection, the threat intelligence to keep on top of current threats, and the tools to respond quickly to incidents. With Cyolo’s robust role-based access, application, and policy control, in the future the Dragos Platform will be able to manage Cyolo’s Identity-based parameters (users, applications, resources, policy) in accordance with SOC / IR policies and guidelines.

Together Cyolo and Dragos deliver a comprehensive ICS/OT security framework based on the five critical controls of effective ICS/OT security:

  • ICS incident response—which integrates operational insights into incident handling, enhancing system integrity and recovery (Dragos)
  • Defensible architecture—ensuring robust visibility, segmentation, and enforcement mechanisms to bridge technological and human aspects of security (Dragos and Cyolo PRO)
  • ICS network visibility monitoring—employing continuous monitoring and protocol-aware tools to detect and address potential vulnerabilities (Dragos)
  • Remote Access Security—ensuring safe and secure stringent access control in the face of evolving hybrid work environments (Cyolo PRO)
  • Risk-based vulnerability management—prioritizing and addressing vulnerabilities based on their potential to pose significant operational risks, thereby ensuring proactive prevention, response, and recovery actions (Dragos and Cyolo PRO)

The solution plans to integrate Cyolo PRO and the Dragos Platform through an API architecture or operator console. It will deliver unsurpassed visibility and control of critical digital assets through secure identity-based access. Together, both companies will deliver simpler, stronger, and more efficient security controls that lay the foundation for Zero Trust (NIST 800-207).

“With this industry leading partnership, Cyolo joins Dragos to address security and operational challenges impacting OT environments," said Joe O’Donnell, EVP Corporate Development and OT GM at Cyolo. “The interoperability of the Dragos Platform and Cyolo PRO provides OT practitioners and industrial organizations with the full spectrum of cybersecurity services across the 5 ICS/OT Critical Controls. The timing could not be better as the world aggressively embraces Industry 4.0.”

Dino Busalachi, CTO and Co-Founder at Velta Technology - a joint partner - also highlighted that “In light of the surge in cyber threats, the growing adoption of Industry 4.0, and the inherent risks within OT environments, Velta Technology understands the critical need to partner with Cyolo and Dragos. Their joint solutions will provide our customers in the industrial sector with a tailored approach that strengthens their access security and elevates their overall security posture.”

Dragos and Cyolo respond to the need for secure industrial networks without disrupting operations, compromising safety or risking non-compliance.

The Dragos Platform offers the most effective industrial cybersecurity technology, giving customers visibility into their ICS/OT assets, vulnerabilities, threats, and response actions. The strength behind the Dragos Platform comes from Dragos’s ability to codify industry-leading OT threat intelligence, and insights from the Dragos services team into the software.

About Cyolo

Cyolo helps IT and ICS organizations stay secure and productive in an era of distributed workforces and unprecedented cyber threats. Cyolo’s platform enables all users, including employees, third parties, and remote or on-site workers, to connect to their working environments seamlessly and securely via modern identity-based authentication. With one unified solution that integrates with your existing tech stack, Cyolo makes securely connecting people to their work simple. To learn more, visit https://cyolo.io

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508290964/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye